跳至主要内容
临床试验/NL-OMON53426
NL-OMON53426尚未招募不适用

The role of skin sodium accumulation in chronic kidney disease - SKIN-CKD

Academisch Medisch Centrum0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Inclusion criteria
  • 1. Chronic kidney disease with an eGFR between 15 and 60 ml/min/1.73m2.
  • 2. Stable diuretic and antihypertensive treatment in the 6 weeks prior to the
  • Additional inclusion criteria for the sodium excretion intervention
  • 1. Office systolic blood pressure (SBP) >135 mmHg

排除标准

  • Exclusion criteria
  • 1. Age <18 years.
  • 2. An eGFR decline >5 ml/min/1.73m2 per year.
  • 3. Proteinuria >3 grams/day.
  • 4. Use of glucocorticoids with an equivalent of prednisolone >5mg/day
  • 5. Use of or a calcineurin inhibitor.
  • 6. Contra-indication for MRI i.e. metallic foreign body, claustrofobia
  • 7. Cardiovascular event in the 3 months prior to the study
  • 8. Patients with active infection and/or auto-immune diseases with involvement
  • of the lower extremities.
  • 9. Presence of significant comorbidities (e.g. advanced malignancy, advanced
  • liver disease) with a life expectancy of less than 1 year.
  • Additional exclusion criteria for sodium intake intervention
  • 1. Chronic use of NSAID
  • Additional exclusion criteria for sodium excretion intervention
  • 1. Serum potassium concentration >5.0 mmol/l.
  • 2. eGFR <30 ml/min/1.73m2
  • 3. Uncontrolled hypertension (>180/100mmHg)
  • 4. Contra-indication for drugs used during this study e.g. drug intolerance
  • (side effect, hyperkalaemia hypersensitivity to sulphonamides) and drug
  • interaction.
  • 5. Chronic use of NSAID.

研究者

相似试验